Literature DB >> 6215581

Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis.

K T Nouri-Aria, J E Hegarty, G J Alexander, A L Eddleston, R Williams.   

Abstract

We detected a severe defect in concanavalin A-induced suppressor-cell activity in 22 patients with "autoimmune" chronic active hepatitis and in 26 patients with hepatitis B surface antigen (HBsAg)-positive chronic active hepatitis, as compared with 20 control subjects (P less than 0.01). Normal values were observed in 21 patients with "autoimmune" hepatitis in whom a remission had been induced and maintained by treatment with prednisolone. When lymphocytes from patients with autoimmune chronic active hepatitis were preincubated with low-dose prednisolone in vitro, suppressor-cell activity was substantially improved (P less than 0.01), but no clear effect of prednisolone was seen in cells from patients with HBsAg-positive chronic active hepatitis. The loss of suppressor-cell activity in chronic active hepatitis may allow liver damage to continue, and the reversal of the defect in the autoimmune form of the disease by administration of low-dose prednisolone provides a plausible explanation for the efficacy of this treatment. The contrasting in vitro responses to prednisolone in autoimmune and HBsAg-positive chronic active hepatitis suggest that the fundamental nature of the suppressor-cell defect may be different in these two forms of the disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6215581     DOI: 10.1056/NEJM198211183072102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  30 in total

1.  Suppressor T-cell deficiency in primary sclerosing cholangitis. Case and family study.

Authors:  A E Kilby; E L Krawitt; R J Albertini; B F Chastenay; A John
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

2.  High serum levels of CD8 antigen in primary biliary cirrhosis: a possible cause of suppressor cell dysfunction?

Authors:  K T Nouri Aria; M Lombard; R Williams
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

Review 3.  Immunological aspects of liver disease.

Authors:  A L Eddleston; P T Donaldson; J E Hegarty; B D Reed
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 4.  Chronic active hepatitis.

Authors:  P J Johnson; I G McFarlane
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 5.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 6.  Cellular mechanisms of hepatocyte damage and regulatory mechanisms in autoimmune chronic active hepatitis.

Authors:  S Vento; A L Eddleston
Journal:  Springer Semin Immunopathol       Date:  1990

7.  Exacerbated autoimmune hepatitis successfully treated with leukocytapheresis and bilirubin adsorption therapy.

Authors:  K Sawada; K Ohnishi; T Kosaka; S Chikano; A Egashira; M Okui; S Shintani; M Wada; K Nakasho; T Shimoyama
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

8.  Importance of adequate immunosuppressive therapy for the recovery of patients with "life-threatening" severe exacerbation of chronic hepatitis B.

Authors:  Keiichi Fujiwara; Osamu Yokosuka; Hiroshige Kojima; Tatsuo Kanda; Hiromitsu Saisho; Hiroyuki Hirasawa; Hiroshi Suzuki
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

9.  A diagnostic marker of autoimmune chronic active hepatitis: liver plasma membrane antibody in the serum absorbed with particulate fraction of kidney homogenate.

Authors:  G Toda; Y Ikeda; N Hashimoto; T Maruyama; H Oka
Journal:  Gastroenterol Jpn       Date:  1987-06

Review 10.  Hepatitis B virus infection. Current concepts of chronicity and immunity.

Authors:  G N Vyas; H E Blum
Journal:  West J Med       Date:  1984-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.